Last reviewed · How we verify
NCT03729349: GO FAR
Golimumab for Adherence in Rheumatoid Arthritis
trial testing Golimumab in Arthritis, Rheumatoid in 222 participants. Completed in 19 June 2023.
19 June 2023
Quick facts
| Lead sponsor | Janssen Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 222 |
| Start date | 15 January 2019 |
| Primary completion | 19 June 2023 |
| Estimated completion | 19 June 2023 |
| Sites | 32 locations across Canada |
Drugs / interventions tested
- Golimumab (GOLIMUMAB) — full drug profile →
Conditions studied
- Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →
Sponsor
Janssen Inc. — full company profile →
Who can join
Adults 18 to 85, any sex, with Arthritis, Rheumatoid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine if non-adherence to Rheumatoid Arthritis (RA) drugs in participants treated with biologic disease modifying anti-rheumatic drugs (DMARDs) is associated with a greater incidence of disease in clinical practice.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study.
Bessette L, Boulos P, Arendse R, Rahman P, et al · · 2025 · PMID 40585577 · DOI 10.2147/ppa.s516794
Verify or expand the search:
- PubMed search for NCT03729349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Golimumab
Trials testing the same drug.
- NCT05960578 — Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study · Phase 2 · active not recruiting
- NCT05242484 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerati · Phase 2 · active not recruiting
- NCT05242471 — A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's · Phase 2 · active not recruiting
- NCT05164198 — REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST) · Phase 4 · unknown
- NCT05071664 — A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis · Phase 2 · completed
Other recruiting trials for Arthritis, Rheumatoid
Currently open trials in the same condition.
- NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
- NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
- NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
- NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
- NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting
Other Janssen Inc. trials
Trials by the same sponsor.
- NCT03501173 — A Study of Participants With Advanced Prostate Cancer in Canada · completed
- NCT02688075 — An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in · completed
- NCT02364531 — A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Sett · completed
- NCT01483599 — A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis · Phase 2 · completed
- NCT00741793 — Biologic Treatment Registry Across Canada · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03729349 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Janssen Inc.
- Last refreshed: 18 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03729349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing